Pubmed (TDAH) du 05/11/26
1. Anderbro T, Chlaidze M, Aarikka V, Nelson M, Svirsky L, Oscarsson M, Andersson G, Ginsberg Y, Carlbring P. Enhancing relationship quality in couples affected by ADHD: a randomized controlled study of a couple’s intervention. Cogn Behav Ther;2026 (Nov 5):1-16.
Attention-Deficit/Hyperactivity Disorder (ADHD) is highly prevalent among adults, making it one of the most common psychiatric diagnoses in this population associated with negative functional impact across multiple life areas, including romantic relationships. Despite this, scientifically evaluated interventions specifically targeting relationship quality in couples where one or both partners have ADHD remain limited. This study presents a randomized controlled evaluation of a couple-based intervention for ADHD, assessing its impact on relationship quality and participants’ experiences. Eighty couples (n = 160 participants) were randomized to either an intervention group or a waitlist control group, with assessments conducted at baseline, post-intervention, and three-month follow-up. Intention-to-treat analyses using Linear Mixed Models indicated no significant between-group difference for the primary outcome of relationship quality (QDR-36), nor for secondary outcomes of stress, depression, anxiety, or ADHD-related quality of life. A significant between-group interaction effect was found for ADHD symptoms (ASRS), however, this effect unexpectedly favored the waitlist control group, which showed a greater reduction in symptoms compared to the intervention group. The participants’ evaluation of the course indicated an overall high rating of satisfaction with the content. Suggestions for improving access to the course as well as improving the course’s effect on relationship quality are discussed.
Lien vers le texte intégral (Open Access ou abonnement)
2. Brashier K, Peppers KH, Shafer S. Narrative Review of the Advantages and Clinical Data to Support Evening Dosing for Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-deficit/Hyperactivity Disorder: A Prescriber Perspective. J Pediatr Health Care;2026 (Nov 5)
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder typically treated first-line with stimulants. This review provides guidance to prescribers by presenting an overview of available treatment options, along with clinical and real-world evidence for delayed-release and extended-release methylphenidate (DR/ER-MPH). Traditional long-acting stimulants differ in duration of effect, leading to gaps in symptom control during the afternoon and evening. DR/ER-MPH is a unique treatment option, administered in the evening and absorbed in the colon, producing a gradual rise and fall in stimulant concentration and a dose-dependent duration of effect, making it a good option for patients across the lifespan. The safety profile of DR/ER-MPH is consistent with other methylphenidate formulations. With the guidance provided here, prescribers can ensure optimal outcomes when transitioning patients with ADHD to DR/ER-MPH treatment.
Lien vers le texte intégral (Open Access ou abonnement)
3. Cobbaert L, Elwyn R, Pavlopoulou G. Beyond the attention economy: Rethinking rising adult ADHD diagnoses in response to Jesudason et al. (2026). Australas Psychiatry;2026 (Nov 5):10398562261505343.
ObjectiveTo argue that current evidence does not justify privileging Jesudason et al.’s attention-economy account of rising adult attention deficit/hyperactivity disorder (ADHD) diagnoses over plausible alternatives, including delayed recognition, historical underdiagnosis and misdiagnosis, and exclusionary diagnostic practices.ConclusionsJesudason et al. appropriately caution against simplistic diagnosis, performance-enhancing stimulant use, and uncritical medicalisation. However, adult diagnosis is not equivalent to adult onset, and increased treatment uptake or prescribing does not establish increased underlying prevalence. Associations between digital use and ADHD characteristics do not resolve causality or directionality. Digital environments may amplify or unmask longstanding ADHD-related difficulties without causing ADHD, while problematic digital use may reflect ADHD-related vulnerabilities. Rising adult diagnoses may also represent diagnostic correction among women, people assigned female at birth, racialised communities, Indigenous and First Nations peoples, and culturally minoritised groups historically missed, misdiagnosed, or routed into punitive frameworks. A balanced account must reject both over-medicalisation and exclusionary diagnostic gatekeeping.
Lien vers le texte intégral (Open Access ou abonnement)
4. Ejerskov C, Jepsen JRM, Krøyer A, Østergaard JR, Doherty MA, Rostgaard K, Hjalgrim H, Hove H, Handrup MM, Mulvihill JJ, Doser K, Bidstrup PE, Kenborg L. Associations of Attention-Deficit/Hyperactivity Disorder Symptoms With Quality of Life and Real-Life Functioning in Adults With Neurofibromatosis Type 1: A Nationwide Questionnaire Study in Denmark. Am J Med Genet A;2026 (Nov 5)
This cross-sectional study investigated associations between screening positive for attention-deficit/hyperactivity disorder (ADHD) and quality of life (QoL), as well as real-life functioning, in 235 adults with neurofibromatosis 1 (NF1). Self-reported data included ADHD symptoms (Adult Self-Report ADHD Scale v1.1), QoL (PedsQL NF1 Module), partner status, and need for daily support, supplemented by registry data on education and employment. Adults screening positive for ADHD (14%) had a mean QoL score that was 16.0 points lower (95% confidence interval [CI]: -20.2 to -11.7) than that of adults who screened negative. Each 1-point increase in inattention or hyperactivity/impulsivity score was associated with a mean decrease in QoL of 0.9 (95% CI: -1.1, -0.7) and 0.5 (95% CI: -0.7, -0.3). Screening positive for ADHD was associated with lower odds of having a medium/long education (odds ratio [OR]: 0.24, 95% CI: 0.10-0.56) and being employed (OR: 0.20, 95% CI: 0.10-0.50), but not with having a partner (OR: 0.73, 95% CI: 0.34-1.56). ADHD was also associated with a greater need for daily support, including physical (OR: 8.7, 95% CI: 3.6-21.1), family-related (OR: 5.7, 95% CI: 2.4-13.3), and psychological (OR: 5.0, 95% CI: 2.2-11.3) support. These results support assessment of ADHD symptoms in adults with NF1 to facilitate timely treatment and care.
Lien vers le texte intégral (Open Access ou abonnement)
5. Eng AG, McGrath FP, Martel MM. Hormonal effects on ADHD symptoms in adolescents across the menstrual cycle. Eur Child Adolesc Psychiatry;2026 (Nov 5)
Female-specific risk factors for ADHD in adolescence have been vastly understudied despite increased impairment and comorbidity during this period. In adults, the premenstrual phase and rapid decreases in estradiol levels are associated with increased risk for ADHD symptoms. The current project aims to evaluate the effects of day-to-day changes in estradiol and progesterone on ADHD symptoms across the menstrual cycle in adolescents. Participants were 13 adolescents aged 12 to 17 years over-recruited for ADHD. Participants collected saliva samples and completed measures of ADHD symptoms daily. Generalized additive mixed models were used to explore symptom trajectories across the menstrual cycle and examine the relationships between hormones and ADHD symptoms. Inattention and hyperactivity severity exhibited significant menstrual cycle-related variation, but average symptom trajectories across the cycle were largely flat. Significant person-specific cycle effects and individual differences in estradiol-symptom associations suggest substantial heterogeneity in menstrual cycle influence on ADHD symptoms. These findings suggest that menstrual cycle-related changes in ADHD symptoms are not characterized by a uniform pattern across adolescents and instead may reflect individual differences in hormone sensitivity. Future research should prioritize identifying distinct hormone-symptom response profiles and determine their clinical relevance for personalized ADHD management.
Lien vers le texte intégral (Open Access ou abonnement)
6. Gupta M, McCall J, Khurana P, Gupta N. Underrecognized suicidality in higher functioning youth with autism spectrum disorder and attention deficit hyperactivity disorder. Discov Ment Health;2026 (Aug 10);6(1)
OBJECTIVE: To examine factors associated with elevated risk of suicidal thoughts, behaviors, and death by suicide among high functioning individuals with autism spectrum disorder and attention deficit hyperactivity disorder, with particular emphasis on phenotypes characterized by high cognitive ability and delayed recognition. METHODS: A structured review of the literature was conducted across multiple electronic databases using controlled vocabulary and key terms including suicidal risk, autism spectrum disorder, attention deficit hyperactivity disorder, high functioning, and neurodivergence. After screening for relevance, duplication, and methodological rigor, 7 studies meeting inclusion criteria were synthesized from an initial yield of fifty publications. RESULTS: Across studies, individuals with ASD demonstrated a consistently elevated risk of STB and death by suicide compared with the general population, both over the lifetime and within shorter follow up periods. Risk was disproportionately concentrated among individuals without intellectual disability, with higher cognitive ability emerging as a vulnerability factor rather than a protective one. Communication differences, alexithymia, and impaired interoceptive awareness limited the sensitivity of caregiver and clinician assessments, contributing to under recognition of suicidality. Traditional protective factors such as educational attainment, employment, and relationship status did not reliably mitigate risk in ASD and ADHD populations. Camouflaging behaviors and diagnostic overshadowing frequently delayed identification, increasing exposure to cumulative psychosocial stress and untreated mental health conditions. CONCLUSIONS: High functioning individuals with ASD and co-occurring ADHD represent a concealed yet high risk population for suicidality. These findings underscore the urgent need for autism informed suicide risk assessment, early identification of neurodevelopmental traits in suicidal individuals, and prevention strategies tailored to cognitive profile, developmental history, and comorbidity. Advances in the current screening and intervention frameworks may mitigate adverse outcomes in this vulnerable group.
Lien vers le texte intégral (Open Access ou abonnement)
7. Oveisi S, Jafari E, Bahari MM, Farshidgohar M. Cardiovascular effects of methylphenidate, risperidone, and their combination in children and adolescents with attention-deficit/hyperactivity disorder: a prospective 3-month observational study. BMC Pediatr;2026 (Aug 6);26(1)
BACKGROUND: We aimed to evaluate changes in hemodynamic parameters and electrocardiographic (ECG) indices related to ventricular arrhythmia risk after three months of treatment with methylphenidate (MPH), risperidone (RIS), or their combination in children and adolescents with ADHD. METHODS: A total of 150 children and adolescents with DSM-5-diagnosed ADHD were prospectively enrolled at Qods Hospital. Participants received methylphenidate (n = 50), risperidone (n = 50), or combination therapy (n = 50). Cardiovascular outcomes were assessed using age- and weight-adjusted two-way repeated-measures ANCOVA to evaluate changes over time and differences among treatment groups. RESULTS: Significant group × time interactions were observed for systolic blood pressure, diastolic blood pressure, heart rate, and QTc interval after adjustment for baseline age and weight. After three months, systolic and diastolic blood pressure increased in the methylphenidate and combination therapy groups, while heart rate showed an overall increase, with the greatest rise observed in the methylphenidate group. QTc interval increased over time across all treatment groups, with the largest prolongation observed in the combination therapy group (377.9 ± 25.4 to 424.5 ± 24.9 ms). However, mean QTc values remained below commonly accepted thresholds for clinically significant QT prolongation, and no significant longitudinal changes were observed in QRS duration or PR intervals. CONCLUSION: Treatment with methylphenidate, risperidone, and combination therapy was associated with modest changes in heart rate, blood pressure, and QTc interval over three months. These findings highlight the importance of baseline and follow-up cardiovascular monitoring in children and adolescents receiving ADHD medications.
Lien vers le texte intégral (Open Access ou abonnement)
8. Uberos J, Carrasco-Solis M, Laynez-Rubio C, Nieto-Ruiz A, Ruiz-López A, Fernández-Marin E, Perez-Iañez R, Campos-Martínez A. Frontal Cortical Volumes Differ by Attention-Deficit/Hyperactivity Disorder Symptom Presentation in School-Aged Children Born Preterm. Acta Paediatr;2026 (Nov 5)
AIM: To investigate whether cortical and subcortical brain volumes differ according to attention-deficit/hyperactivity disorder (ADHD) symptom presentation in school-aged children born very preterm. METHODS: This cross-sectional study included 81 children born before 32 weeks of gestation: 64 without ADHD symptoms, 7 with predominantly inattentive symptoms and 10 with combined symptoms, classified using the Vanderbilt parent questionnaire. Magnetic resonance imaging was analysed using FreeSurfer. General linear models were adjusted for gestational age, birth weight, sex and total intracranial volume. False discovery rate (FDR) correction was applied. RESULTS: Left rostral middle frontal gyrus (RMFG) volume was the only region significantly associated with symptom presentation after FDR correction (partial η(2) = 0.179; p = 0.030). Adjusted RMFG volume was larger in children with combined symptoms than in those without ADHD symptoms (mean difference, 3610 mm(3); 95% CI, 1155-6064; adjusted p = 0.002). The inattentive group had the lowest adjusted mean volume, but the difference from the asymptomatic group was not significant. RMFG volume correlated positively with inattentive and hyperactivity/impulsivity symptom scores. No other regional associations remained significant after correction. CONCLUSION: ADHD symptom presentation was associated with left RMFG volume, showing a non-monotonic pattern across groups. Larger longitudinal studies are needed to clarify the developmental significance of these findings.
Lien vers le texte intégral (Open Access ou abonnement)
9. Zhang XJ, Chen XN, Zhang Y, Kam KW, Wong ICK, Zhang W, Young AL, Tham CC, Pang CP, Chen LJ, Ip P, Yam JC. Retinal nerve fibre layer, and ganglion cell layer thicknesses in children with ADHD: associations with subtypes and symptom severity. BMC Psychiatry;2026 (Aug 7);26(1)
BACKGROUND: To investigate retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL) thickness in different attention-deficit/hyperactivity disorder (ADHD) subtypes and their association with ADHD symptom severity. METHODS: This is a cross-sectional study included children aged 6-8 years in Hong Kong. ADHD diagnoses were made by psychiatrists based on ICD-10 criteria. RESULTS: Among 6431 children included in the study, 309 (4.80%) were diagnosed with ADHD and 6122 served as controls. Children with ADHD showed thinner p-RNFL, m-GCL, and p-GCL than controls (P = 0.002; P = 0.03; P = 0.003, respectively). Among the 309 ADHD, 149 were categorized as the combined (C) type, 74 as the Inattentive (IA) type, 39 as the hyperactive/impulsive (HI) type. The ADHD-C subtype exhibited thinner p-RNFL (mean difference [MD] = -2.47, P = 0.03), m-GCL (MD = -1.10, P = 0.03), and p-GCL (MD = -0.85, P = 0.007) than controls. The p-RNFL, m-GCL, and p-GCL thicknesses showed a decreasing trend across ADHD subtypes, being thickest in the ADHD-HI, followed by the IA, and then the C subtype (P = 0.04, P = 0.005, and P = 0.04, respectively). Higher SWAN-combined scores were associated with thinner p-RNFL, m-GCL, p-GCL, and m-RNFL (P = 0.04; P = 0.002; P = 0.005; P = 0.02, respectively). CONCLUSION: RNFL and GCL thicknesses varied across ADHD subtypes. The combined subtypes exhibited thinner measurements than controls. An overall trend toward thinner RNFL and GCL thicknesses was observed across subtypes. RNFL and GCL thicknesses were negatively associated with severity of combined ADHD symptoms. CLINICAL TRIAL NUMBER: Not applicable.